AEGiS-PRn: ONCORx Inc. Holds 3-TC Patent Pending Rights to Treat Hepatitis B Virus

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

ONCORx Inc. Holds 3-TC Patent Pending Rights to Treat Hepatitis B Virus

PR Newswire - November 6, 1995

NEW HAVEN, Conn., Nov. 6 /PRNewswire/ -- Following today's announcement that the Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee recommended approval of the anti-HIV and -HBV drug known as "3-TC," John A. Spears, the President and C.E.O. of the New Haven, Connecticut-based OncoRx, Inc. (Nasdaq: OCRX), announced satisfaction with the outcome of today's FDA advisory committee recommendation.

"We are pleased with today's FDA Advisory Committee's action regarding the drug 3-TC (which is also known as Lamivudine). It is of particular interest to our company because OncoRx holds exclusive rights to a U.S. patent application for this antiviral agent, 3-TC, in the treatment of Hepatitis B virus (HBV). The application was filed in the U.S. in 1991 by Yale University; OncoRx licensed the exclusive rights from Yale in 1994. OncoRx has also licensed exclusive rights to patent applications on several other antiviral agents having activity against HBV and HIV."

3-TC is currently being developed by Glaxo Wellcome for use in the treatment of HIV and HBV. Clinical studies indicate that 60 percent of people with HIV/AIDS are infected with HBV.

OncoRx is a biopharmaceutical company dedicated to discovering, developing and marketing oncology products. The Company expects to introduce several novel anticancer agents into clinical trials by 1999. Through in-licensing and acquisitions, OncoRx will be marketing oncology-related products to target segments of the oncology market.

CONTACT: Thomas Klein of OncoRx, 203-498-4210 or Reva J. Wayman of Harrison, Star, Wiener & Beitler PR, 212-689-3690/ 18:20 EST

Copyright (c) 1995/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
951106
PR951114

Copyright © 1995 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .